• About online consultations

  • 30 Consultation


  • 60 Consultation

  • 30 min Review & 30 min Consultation
    ※Online consultation will be in the latter 30 minutes.
    ※Please send the manuscript by 2-5 days prior to the date of the session(consult@enago.com)

Clement Weinberger

Country: United States of America


Qualification: Ph.D. in Cell Biology; New York University



Communication style

Experienced mentor, will speak slow in easy English, and has interacted with ESL researchers.


  1. Instructor profile
Clement is a well-published author and he has a good amount of experience in the area of scientific editing. He is a successful entrepreneur and he has held important positions in industry. Clement is available for consultation sessions on topics related to academic writing and publishing.
Education
  • Ph.D., Cell Biology, New York University, NY, USA 1976
  • M.S., Cell Biology, New York University, NY, USA 1974
  • B.S., Biology, Fairleigh Dickinson University, NJ, USA 1967
Publications
  • Arnoux S, Weinberger C, Gessner BD. Vaccine-preventable influenza disease burden from clinical trials of Vaxigrip – an inactivated split virion influenza vaccine - supports wider vaccine use. Vaccine 2007;25(45):7720–31.
  • Bonnet MC, Dutta A, Weinberger C, Plotkin SA. Mumps vaccine virus strains and aseptic meningitis. Vaccine 2006;24(49–50):7037–45.
  • Brick, I., and Weinberger, C. (1984). Electrophoretic properties, cell surface morphology, and calcium in amphibian gastrulation. Am. Zool. 1984;24:629–647.
  • Dutta AK, Weinberger C, Houillon G, Rassouli A, Worldwide experience with a purified vero-cell-culture rabies vaccine.
  • APCRI J 2006;8. epub available from: http://www.apcri.org/v8wrdwd.htm
  • Dutta A, Weinberger C, Bonnet M-C. Haemophilus influenzae type b conjugate vaccines: efficacy and safety. Asian-Oceanian Journal of Pediatrics and Child Health 2004;3(2):80–89.
  • Helson L, Weinberger C, Helson C, Lieberman P. Neuroectodermal tumor and monoclonal antibodies. Am J Pediatr Hematol Oncol. 1984;6(3):227–31.
  • Helson L, Helson C, Weinberger C. Immunoreactive prothrombin-like material in hepatoblastoma and other tumor monolayers. Pediatric hematology and oncology 1983;1(1):85–7.
  • Primary hypoblast development in the chick I. Scanning electron microscopy of normal development. Devel Genes Evol 1982;191:119–126.
  • Weinberger CP, Brick I. Locomotion and adhesion of amphibian gastrula and neurula cells cultured on substrata of varied surface charge. Exp Cell Res 1980;130(2):251–63.
  • Weinberger C, Penner PL, Brick I. Polyingression, an important morphogenetic movement in chick gastrulation. Am. Zool 1984;24(3):545–54.
Publications with acknowledgment of writing assistance Vaccine-related:
  • Abarca K, Ibánez I, Perret C, Vial P, Zinsou JA. Immunogenicity, safety, and interchangeability of two inactivated hepatitis A vaccines in Chilean children. Int J Infect Dis 2008;12(3):270–7.
  • Aquino AG, Brito MG, Doniz CE, Herrera JF, Macias M, Zambrano B, Plennevaux E, Santos-Lima E. A fully liquid DTaP-IPV-Hep B-PRP-T hexavalent vaccine for primary and booster vaccination of healthy Mexican children Vaccine. 2012;
  • Avila Aguero ML, Soriano-Fallas A, Umaña-Sauma MA, Ulloa-Gutierrez R, Arnoux S. Immunogenicity and tolerability of inactivated flu vaccine in high risk and healthy children. Medicina (B Aires) 2007;67(4):351–9.
  • Bonnet MC, Dutta A. World wide experience with inactivated poliovirus vaccine. Vaccine 2008;26(39):4978–83.
  • Capeding MR, Cadorna-Carlos J, Book-Montellano M, Ortiz E. Immunogenicity and safety of a DTaP-IPV//PRP-T combination vaccine given with hepatitis B vaccine: a randomized open-label trial. Bull World Health Organ 2008;86(6):443–51.
  • Ceyhan M, Yildirim I, Kurt N, Uysal G, Dikici B, Ecevit C, Aydogan A, Koc A, et al. Differences in hepatitis A seroprevalence among geographical regions in Turkey: a need for regional vaccination recommendations. J Viral Hepatitis 2008; 15(Suppl. 2): 69–72.
  • Dutta A. Epidemiology of poliomyelitis–options and update. Vaccine. 2008 Oct 23;26(45):5767–73.
  • Dutta AK, Verghese VP, Pemde HK, Mathew LG, Ortiz E. Immunogenicity and safety of a pentavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b conjugate combination vaccine (Pentaxim™) at 6, 10, 14 weeks of age. Indian Pediatrics 2009;46:975–982. http://indianpediatrics.net/index.htm
  • Espul C, Benedetti L, Cuello H, Houillon G, Rasuli A. Persistence of immunity from one year of age after one or two doses of hepatitis A vaccine given to children in Argentina. Hepat Med 2012;4:53–60.
  • Frey S, Vesikari T, Szymczakiewicz‐Multanowska A, Lattanzi M, Izu A, Groth N, Holmes S. Clinical efficacy of cell culture-derived and egg‐derived inactivated subunit influenza vaccines in healthy adults. Clin Infect Dis 2010;51:000–000 http://www.journals.uchicago.edu/doi/abs/10.1086/656578
  • Gold R, Barreto L, Ferro S, Thippawong J, Guasparini R, Meekison W, et al. Safety and immunogenicity of a fully liquid vaccine containing five-component pertussis-diphtheria-tetanus-inactivated poliomyelitis-Haemophilus influenzae type b conjugate vaccines administered at 2, 4, 6 and 18 months of age. Can J Infect Dis Med Microbiol 2007;18(4):241–8.
  • Fisenka EG, Germanovich, FA Glinskaya IN, Lyabis OI, Rasuli AM. Effectiveness of universal hepatitis A immunization of children in Minsk City, Belarus: four-year follow-up. J Viral Hepatitis 2008;15(Suppl2): 57–61.
  • Kuanprasert S, Apichartpikul N, Chuenkitmongkol S, Wiangosot W, Topaiboon P, Sukonthasarn A. Evidence of influenza or influenza-like-illness preceding acute coronary syndrome. Southeast Asian J Trop Med Public Health 2008;39(6):1040–4.
  • Kmiecik T, Arnoux S, Kobryn A, Gorski P. Influenza vaccination in adults with asthma: safety of an inactivated trivalent influenza vaccine. J Asthma. 2007;44(10):817–22.
  • Lang J, Feroldi E, Vien NC. Pre-exposure purified vero cell rabies vaccine and concomitant routine childhood vaccinations: 5-year post-vaccination follow-up study of an infant cohort in Vietnam J of Trop Pediatr 2009;55(1):26–31.
  • Lee SY, Hwang HS, Kim JH, et al. Immunogenicity and safety of a combined diphtheria, tetanus, acellular pertussis, and inactivated poliovirus vaccine (DTaP-IPV) compared to separate administration of standalone DTaP and IPV vaccines: A randomized, controlled study in infants in the Republic of Korea. Vaccine. 2011;29(8):1551–7.
  • Li RC, Li FX, Li YP, et al. Immunogenicity and safety of a pentavalent acellular pertussis combined vaccine including diphtheria, tetanus, inactivated poliovirus and conjugated Haemophilus Influenzae type b polysaccharide for primary vaccination at 2, 3, 4 or 3, 4, 5 months of age in infants in China. Vaccine 2011 Feb 24;29(10):1913–20.
  • Li RC, Li YP, Yi N, et al, An open, prospective, randomized study comparing the immunogenicity and safety of two inactivated hepatitis A pediatric vaccines in toddlers, children and adolescents in China. Pediatr Infect Dis J 2012 (4 September, doi: 10.1097/INF.0b013e318271c4c3)
  • Madhi SA, Cutland C, Jones S, Groome M, Ortiz E. Immunogenicity and safety of an acellular pertussis, diphtheria, tetanus, inactivated poliovirus, Hib-conjugate combined vaccine (Pentaxim™) and monovalent hepatitis B vaccine at 6, 10 and 14 weeks of age in infants in South Africa. S Afr Med J 2011;101:126–131.
  • Ripoll C, Ponce A, Wilson MM, Sharif N, Vides JB, Armoni J, Teuwen DE. Evaluation of two yellow fever vaccines for routine immunization programs in Argentina. Hum Vaccin 2008;4(2):121–6.
  • Thisyakorn U, Pancharoen C, Chuenkitmongkol S, Ortiz E. Immunogenicity and safety of a DTaP-IPV//PRP-T vaccine (PentaximTM) booster during the second year of life in Thai children primed with an acellular pertussis combined vaccine. Southeast Asian J Trop Med Public Health 2009;40(2):282–94.
  • Thisyakorn U, Chotpitayasunondh T, Pancharoen C, Chuenkitmongkol S, Ortiz E. Evaluation of an acellular pertussis, diphtheria, tetanus, inactivated poliovirus, HIBconjugate combined vaccine (PentaximTM) at 2, 4, and 6 months of age plus hepatitis B vaccine at birth, 2, and 6 months of age in infants in Thailand. Southeast Asian J Trop Med Public Health 2010;41(2):250–262.
  • Vesikari T, Karvonen A, Tilman S, Borkowski A, Montomoli E, Banzhoff A, Clemens R. Immunogenicity and safety of MF59-adjuvanted H5N1 influenza vaccine from infancy to adolescence. Pediatrics. 2010;126(4):e762–70.
  • Weil-Olivier C, van der Linden M, de Schutter I, Dagan R, Mantovani L. Prevention of pneumococcal diseases in the post-seven valent vaccine era: A European perspective. BMC Infect Dis 2012, 12:207.
  • Yurdakök K, Bakir M, İnce T, et al. Immunogenicity and safety of an inactivated hepatitis A vaccine given with measles-mumps-rubella vaccine to 12–13-month-old Turkish Children. J Vaccines Vaccin 2012; 3:146.
Infectious diseases:
  • Adelglass J, Bundy JM, Woods R. Efficacy and tolerability of cefprozil versus amoxicillin/clavulanate for the treatment of adults with severe sinusitis. Clin Ther 1998;20(6):1115–29.
  • Dardick K. Educating travelers about malaria: dealing with resistance and patient noncompliance. Cleve Clin J Med 2002;69(6):469–79.
  • Elewski BE, Leyden J, Rinaldi MG, Atillasoy E. Office practice-based confirmation of onychomycosis: a US nationwide prospective survey. Arch Intern Med 2002;14;162(18):2133–8.
  • Garrelts JC, Wagner DJ. The pharmacokinetics, safety, and tolerance of cefepime administered as an intravenous bolus or as a rapid infusion. Ann Pharmacother 1999;33(12):1258–61. DOI 10.1345/aph.19067
  • Moyle G. Use of HIV protease inhibitors as pharmacoenhancers. AIDS Read 2001;11(2):87–98.
Diabetes:
  • Haller H. Postprandial glucose and vascular disease. Diabetic Med 1997;14(S3):S50–S56,
  • Liebl A. Challenges in optimal metabolic control of diabetes. Diabetes Metab Res Rev 2002;18(Suppl 3):S36–41.
  • Yki-Järvinen H. Combination therapy with insulin and oral agents: optimizing glycemic control in patients with type 2 diabetes mellitus. Diabetes Metab Res Rev 2002;18(Suppl 3):S77–81.
Obesity:
  • Dujovne CA, Zavoral JH, Rowe E, Mendel CM; Silbutramine Study Group. Effects of sibutramine on body weight and serum lipids: a double-blind, randomized, placebo-controlled study in 322 overweight and obese patients with dyslipidemia. Am Heart J 2001;142(3):489–97.
  • Fernstrom MH. Treating obesity in the family practice setting. Postgrad Med 2001;109(6 Suppl):10–8.
  • Glazer G. Long-term pharmacotherapy of obesity 2000: a review of efficacy and safety. Arch Intern Med 2001;13–27;161(15):1814–24.
  • Hauner H. Current pharmacological approaches to the treatment of obesity. Int J Obes Relat Metab Disord 2001;25(Suppl1):S102–6.
  • Phelan S, Wadden TA. Combining behavioral and pharmacological treatments for obesity. Obes Res 2002;10(6):560–74.
  • Wadden TA. Exploring synergies in the treatment of obesity. Postgrad Med. 2001;109(6 Suppl):29–33.
  • Wolf AM. The economic impact of obesity. Building bridges with managed care. Postgrad Med.2001;109(6 Suppl):34–9.
Oncology:
  • Chlebowski RT. Factors influencing the role of bisphosphonates in breast cancer management. Semin Oncol 2001;28(4 Suppl 11):42–8.
  • Friedman HS, Kerby T, Calvert H. Temozolomide and treatment of malignant glioma. Clin Cancer Res 2000;6(7):2585–97.
  • Slack JL, Samuel Waxman S, Guido Tricot G, et al. Advances in the management of acute promyelocytic leukemia and other hematologic malignancies. The Oncologist 2002;7(Suppl 1):1–13.
  • Syrigos KN, Pliarchopoulou K, Harrington KJ. The development of monoclonal antibody therapy in leukemias. Hybridoma 2001;20(3):145–8.
  • Yung WK, Albright RE, Olson J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 2000;83(5):588–93
  • Hematopoietic growth factors
  • Brandberg Y. Assessing the impact of cancer-related anemia on quality of life and the role of rHuEPO. Med Oncol 2000;17(Suppl 1):S23–31.
  • Coiffier B. The impact and management of anemia in haematological malignancies. Med Oncol 2000;17(Suppl 1):S2–10.
  • Da Costa RM, Ribeiro Jesus FM, Aniceto C, Mendes M. Granulocyte-macrophage stimulating factor in patients with chronic venous leg ulcers. Wound Repair Regen 1999;7(1):17–25.
  • Erslev AJ. Erythropoietin and anemia of cancer. Eur J Haematol 2000;64(6):353–8.
Epilepsy:
  • Bebin EM. Additional modalities for treating acute seizures in children: overview. J Child Neurol 1998;13(Suppl 1):S23–6
  • Pellock JM Use of midazolam for refractory status epilepticus in pediatric patients. .J Child Neurol 1998;13(12):581–7.
  • Towne AR, DeLorenzo RJ. Use of intramuscular midazolam for status epilepticus. J Emerg Med 1999;17(2):323–8.

Read More >> Read Less >>

Book an Appointment

Consultation

$49 | 30 minutes

Consultation

$89 | 60 minutes

30 min Review & 30 min Consultation

$89 | 30 minutes